NovoPen® 5 wins the red dot Best of the Best design award
2 July 2012 | By Novo Nordisk
Novo Nordisk awarded the red dot Best of the Best prize for its next-generation insulin injection pen, the NovoPen® 5...
List view / Grid view
2 July 2012 | By Novo Nordisk
Novo Nordisk awarded the red dot Best of the Best prize for its next-generation insulin injection pen, the NovoPen® 5...
21 June 2012 | By Novo Nordisk
The decision to initiate the global phase 3 development programme for semaglutide announced...
20 June 2012 | By Novo Nordisk
Novo Nordisk is hosting a side-event during the UN conference, Rio+20, on sustainable development...
13 June 2012 | By Novo Nordisk
Focus will be on disease-modifying immunotherapies for type 1 diabetes...
12 June 2012 | By
One in four people with type 2 diabetes did not dose their long-acting (basal) insulin correctly...
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
8 June 2012 | By Novo Nordisk
Regulatory review period extended for insulins degludec & insulin degludec/insulin aspart...
25 May 2012 | By Novo Nordisk
Novo Nordisk receives a positive opinion on recombinant factor XIII product (rFXIII)...
2 May 2012 | By Novo Nordisk
Novo Nordisk A/S has entered into an agreement to purchase 5,100,000 B shares...
27 April 2012 | By Novo Nordisk
Sten Scheibye has been elected to the Board of the Novo Nordisk Foundation...
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
17 April 2012 | By Novo Nordisk
Novo Nordisk broke ground on a new USD 100 million plant that will formulate and fill modern insulin into Novo Nordisk’s Penfill® cartridges...
24 January 2012 | By Novo Nordisk
Novo Nordisk announced that the company will establish a type 1 diabetes R&D center in Seattle, US...
6 December 2011 | By Novo Nordisk
Insulin degludec / insulin aspart reduced rates of hypoglycaemia by 58%...